Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 12, Issue 2, 2001, Pages 177-184

  Halkin, Amir ^a   Roth, Arie ^a   Jonas, Michael ^b   Behar, Solomon ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Ischemic preconditioning; Myocardial infarction; Sulfonylurea compounds; Thrombolysis

Indexed keywords

ACARBOSE; ARGATROBAN; FIBRINOLYTIC AGENT; HEPARIN; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; STREPTOKINASE; SULFONYLUREA DERIVATIVE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOPLASTY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEART INFARCTION PREVENTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; RETROSPECTIVE STUDY;

AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; SURVIVAL RATE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0035689486     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012979622945     Document Type: Article

References (29)

1. Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: A statewide study
2. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction
3. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
4. The sulfonylurea controversy: More questions from the heart
5. Diabetes and coronary artery disease: Time to stop taking the tablets?
6. Sulfonylurea receptors and mechanism of sulfonylurea action
7. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited
8. Glibenclamide prevents coronary vasodilatation induced by beta 1-adrenoreceptor stimulation in dogs
9. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator-1 in caucasian patients with non-insulin-dependent diabetes mellitus
10. Plasminogen activator inhibitor-1 in non-obese subjects with non-insulin-dependent diabetes mellitus
11. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes
12. Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients
13. Hemobiological properties of gliclazide
14. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus
15. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
16. Sulfonylurea and mortality in diabetic patients after myocardial infarction
17. Arrhythmias and mortality after myocardial infarction in diabetic subjects. Relation to diabetes treatment
18. Myocardial infarction diabetic vs. non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)
19. Argatroban vs. heparin as adjuvant therapy to thrombolysis for acute myocardial infarction
20. A study of the effects of hypoglycemic agents on vascular complications of patients with adult-onset diabetes
21. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus
22. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with 2 diabetes (UKPDS 33)
23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
24. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction
25. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery
26. + channel blocker
27. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease
28. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus